The results of this study, called SHARP (Sorafenib HCC –hepatocellular carcinoma– Assessment Randomized Protocol) allow overall survival (OS) and time to symptom progression (TTSP) comparison between patients who were administered Sorafenib orally, (developed by BAYER) and another group of patients, treated with placebo. The results presented by Clínic-IDIBAPS investigators have been hand selected to be included on the Best of ASCO program. This is an educational initiative that condenses highlights from ASCO’s Annual Meeting into a 1½ day program.
Results are consistent and significant. Overall survival of patients treated with Sorafenib was in average 10.7 months compared to 7.9 months within the group administered placebo. Thus, this treatment increases overall survival by more than 40% if compared to the placebo group. Furthermore, no differences were observed in the severe side effects rate between the treatment’s two modalities. Obtained data imply an unprecedented therapeutic progress in the treatment of advanced liver cancer and involve a shift in this disease’s paradigm. This treatment gives new hope for patients who, until now, could neither beneficiate from curative effects of therapies nor hope for survival improvement. From a scientific point of view, this drug, which delays tumor progression and improves survival, will be the base for future further research.
The SHARP study, an international phase III trial, lead by Hospital Clínic in collaboration with Mount Sinai, where Dr. Llovet is head of the Hepatic Cancer Research Program, started 5 years ago and included a total of 602 patients from 110 centers from the USA, South America, Europe, Australia and New Zealand. All participating patients suffered from advanced liver cancer and had not received any kind of therapy prior to the study.
As a consequence of the good results showed by patients treated with Sorafenib, researchers decided to end the study ahead of schedule in order to administer the drug also to the rest of patients participating in this trial.
Liver cancer and Sorafenib
Primary liver cancer, also known as hepatocellular carcinoma, is the most common of liver cancers. This is the fifth most common cancer worldwide and, in Spain, this disease has an incidence of 10-11 new cases per 100,000 inhabitants per year. The most affected patients are those suffering from acute cirrhosis caused by hepatitis B/ C infections or by excessive alcohol consumption.
Until now, patients suffering from liver cancer in an initial phase have benefited from procedures like resection, transplantation or ablation. Unfortunately, more than 60% of cases of liver cancer are detected in an advanced phase, making chemoembolisation the only available treatment. Chemoembolisation could only be applied to 15% of patients, and there was no other effective treatment for the rest of patients.
Sorafenib blocks a cellular cycle signal pathway, preventing not only the proliferation of tumor cells but also the formation of blood vessels supporting the tumor. Therefore, it delays tumor progression and, as a consequence, improves survival. This implies a hopeful change for patients since until now, treatments tried to eradicate the disease, whereas these new type of agents try to stop the progression of the disease. If new drugs or new combinations of drugs achieve total inhibition of cancer progression, cancer as a whole, and liver cancer in particular, will not necessarily give rise to death.
Hospital Clínic at ASCO
The ASCO Annual Meeting, celebrated this year in Chicago from June 01 – 05 is considered to be the world’s most important event for the whole scientific community conducting research on issues related to cancer, which has more than 30,000 researchers. Every year thousands of articles from all over the world are presented at ASCO, reflecting the last clinical and translational research progress within the areas of prevention, diagnosis and treatment of cancer.
The important role of Hospital Clínic’s presence at the ASCO Annual Meeting is centered in the presence of Dr. Jordi Bruix and Dr. Josep María Llovet from the Hepatic Oncology Group of Hospital Clínic-IDIBAPS, who have participated in today’s plenary session, 04th June at 1 p.m. The plenary session is the central event of this conference, only holding the presentation of results of four chosen research works.
Furthermore, Dr. Joan Bladé and Dr. Laura Rosiñol, both from the Haematooncology Group of Hospital Clínic-IDIBAPS participated in two oral presentations about two new multiple myeloma studies.
These events strengthen Hospital Clinic’s commitment in being an oncological reference hospital not only for the development of translations researches, but also for patient health care.
Àlex Argemí Saburit | alfa
Bare bones: Making bones transparent
27.04.2017 | California Institute of Technology
Link Discovered between Immune System, Brain Structure and Memory
26.04.2017 | Universität Basel
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
20.04.2017 | Event News
18.04.2017 | Event News
03.04.2017 | Event News
27.04.2017 | Life Sciences
27.04.2017 | Physics and Astronomy
27.04.2017 | Earth Sciences